This article first appeared on GuruFocus .
Fifteen ETFs were buying Glaukos ( GKOS ) versus seven selling on Tuesday, a net inflow of $385.0 million by dollar value. ETF activity extended a modest run of net buying: $3.7 million on Nov. 2, $0.3 million on Oct. 30 and a net outflow of $0.9 million on Oct. 29. The buying streak now stands at three consecutive days.
See all ETF and guru trades in GKOS on its GKOS guru trades page .
Which ETFs bought GKOS on Tuesday?
The largest buyers by dollar value were IJH ($497.6 million), SPMD ($75.3 million) and IJK ($58.0 million). In all, 15 ETFs added shares and 7 cut them.
| ETF |
Shares changed |
Value |
Weight in ETF |
|---|---|---|---|
| +2,135,334 |
$497.6M |
0.40% |
|
| +323,332 |
$75.3M |
0.40% |
|
| +248,726 |
$58.0M |
0.55% |
|
| +93,127 |
$21.7M |
0.25% |
|
| +67,000 |
$15.6M |
0.55% |
|
| +36,137 |
$8.4M |
0.03% |
|
| +16,165 |
$3.8M |
0.01% |
|
| +9,525 |
$2.2M |
0.01% |
IJH accounted for the largest share of the move, adding 2,135,334 shares for a value change of $497.6 million at a 0.4% weight. SPMD added 323,332 shares ($75.3 million) and IJK added 248,726 shares ($58.0 million), while IJJ ($21.7 million) and MDYG ($15.6 million) also increased positions. Glaukos sits in the Healthcare sector and Medical Devices industry with a market cap of $14.6 billion.
Have ETFs been buying or selling GKOS lately?
Over the last 4 reported days, ETFs were net buyers on 3 and net sellers on 1, so the recent trend is mostly buying.
| Date |
Net value |
Buying |
Selling |
|---|---|---|---|
| Nov. 3 |
$385.0M |
15 |
7 |
| Nov. 2 |
$3.7M |
10 |
5 |
| Oct. 30 |
$0.3M |
8 |
5 |
| Oct. 29 |
-$0.9M |
7 |
4 |
What does GKOS do?
Glaukos Corp is a US-based ophthalmic medical technology and pharmaceutical company focused on treatments for glaucoma, corneal disorders, and retinal diseases. Its commercial portfolio includes the iStent family of micro-scale surgical devices, such as iStent, iStent inject W, and iStent infinite, which are implanted during cataract or standalone glaucoma surgery to improve aqueous outflow.
Glaukos reported trailing-12-month revenue of $690.3 million, up 41.2% over one year, with a gross margin of 81.1% and a net margin of -24.6%. The stock trades at a P/B of 20.35 and a P/S of 21.11, with a market cap of $14.6 billion. Its GF Score is 75, and at a price of $246.70 it sits above the GF Value of $173.97. The shares have returned 118.49% year to date.
GKOS at a glance
| Measure |
Value |
|---|---|
| Price |
$246.70 |
| Market cap |
$14.60B |
| Revenue (trailing 12 months) |
$690.3M |
| Revenue growth (1 year) |
+41.2% |
| Gross margin |
81.1% |
| Net margin |
-24.6% |
| P/B |
20.35 |
| P/S |
21.11 |
| 75/100 |
|
| GF Value |
$173.97 |
| Year-to-date return |
+118.49% |
For a closer look, open the GKOS stock summary , its GF Value chart and insider buying and selling .
What should investors watch next for GKOS?
Watch whether the three-day net buying streak continues, and whether the inflow stays concentrated in IJH , which drove most of Tuesday's dollar value.
Based on ETF holdings changes reported for Nov. 3, 2026.
Track the latest ETF buying and selling trends and search funds in the GuruFocus ETF Screener .
